SURGICAL TREATMENT OF REGIONAL RECURRENCE FROM GASTRIC CANCER AFTER MULTIMODAL TREATMENT WITH NEOADJUVANT CHEMORADIOTHERAPY (A CASE REPORT)

Background. Gastric cancer is the fourth most common cancer and the second leading cause of cancer-related death worldwide. Despite many advances in the diagnosis and treatment of gastric cancer, the overall five-year survival rate does not exceed 25–30 %, and distant metastases and loco-regional recurrence develop in more than 50 % of patients. Disease recurrence is not only associated with the presence of tumor micro-metastases at the time of surgery, but also with dissemination of tumor cells during mobilization of the stomach or lymph node dissection. Even after performing radical surgery, the prognosis remains extremely unfavorable. No standardized methods of treatment for isolated loco-regional recurrence have been developed yet. Cases of successful treatment of distant metastases and regional recurrence are sporadic. Case report. We present the case of a 75-year-old patient with histologically proven well-differentiated tubular adenocarcinoma of the stomach. The patient underwent neoadjuvant chemoradiation therapy (total radiotherapy dose was 45 Gy, modified Capox regimen) followed by gastrectomy and D2lymph node dissection. The control examination revealed an isolated regional recurrence of gastric cancer. It was decided to perform surgical treatment for isolated regional gastric cancer recurrence. Conclusion. There is no standardized approach to the treatment of regional recurrence of gastric cancer. Surgical treatment in such cases is a method of choice, especially for patients who previously received neoadjuvant chemoradiotherapy. According to the worldwide literature, the median survival of such patients does not exceed a few months. The key point that determines the effectiveness of neoadjuvant therapy is the achievement of complete or partial pathological response to therapy, thus demonstrating improved survival compared to surgery alone. Therefore, it is extremely important to search for immunohistochemical and molecular genetic markers for predicting tumor response to neoadjuvant therapy in order to administer it for only potential responders.

1. D’Angelica M., Gonen M., Brennan M.F., Turnbull A.D., Bains M., Karpeh M.S. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg. 2004 Nov; 240 (5): 808–816. doi: 10.1097/01. sla.0000143245.28656.15

2. Muratore A., Zimmitti G., Lo Tesoriere R., Mellano A., Massucco P., Capussotti L. Low rates of loco regional recurrence following extended lymph node dissection for gastric cancer. Eur J Surg Oncol. 2009 Jun; 35 (6): 588–92. doi: 10.1016/j.ejso.2008.12.012.

3. Lehnert T., Rudek B., Buhl K., Golling M. Surgical therapy for loco regional recurrence and distant metastasis of gastric cancer. Eur J Surg Oncol. 2002 Jun; 28 (4): 455–61.

4. Yoo C.Y., Noh S.H., Shin D.W. Choi S.H., Min J.S. Recurrence fol lowing curative resection for gastric carcinoma. Br J Surg. 2000 Feb; 87 (2): 236–42. doi: 10.1046/j.1365 2168.2000.01360.x.

5. Dikken J.L., van de Velde C.J., Coit D.G., Shah M.A., Verheij M., Cats A. Treatment of resectable gastric cancer. Therap Adv Gastroenterol. 2012 Jan; 5 (1): 49–69. doi: 10.1177/1756283X11410771.

6. Takebayashi K., Murata S., Yamamoto H., Ishida M., Yamaguchi T., Kojima M., Shimizu T., Shiomi H., Sonoda H., Naka S., Mekata E., Okabe H., Tani T. Surgery induced peritoneal cancer cells in patients who have un dergone curative gastrectomy for gastric cancer. Ann Surg Oncol. 2014 Jun; 21 (6): 1991–7. doi: 10.1245/s10434 014 3525 9.

7. Vashakmadze L.A., Butenko A.V., Savinov V.A., Petrova V.V. The abil ity to perform multivisceral resections with a regional recurrence of stom ach cancer. Russian Oncology Journal. 1998; 4: 53–54. [in Russian]

8. Afanasyev S.G., Dobrodeev A.Ju. Cytoreductive surgery (Should the primary tumor be removed? (What is the optimal cytoreduction?). Practical Oncology. 2014; 15 (2): 93–100. [in Russian]

9. Koukourakis G.V. Evidence based radiation therapy for locally advanced resectable and unresectable gastric cancer. World J Gastrointest Oncol. 2011 Sep 15; 3 (9): 131–6. doi: 10.4251/wjgo.v3.i9.131.

10. Aoyama T., Yoshikawa T. Adjuvant therapy for locally advanced gastric cancer. Surg Today. 2017 Nov; 47 (11): 1295–1302. doi: 10.1007/ s00595 017 1493 y.

11. Skoropad V.Yu., Titova L.N., Silantieva N.K., Agababyan T.A., Moserov S.A. Chemoradiotherapy with regional recurrence of stomach cancer. Oncology. Journal of them. P.A. Herzen. 2015; 5: 49–52. doi: 10.17116 / onkolog20154549 52. [in Russian]

12. Ronellenfitsch U., Schwarzbach M., Hofheinz R., Kienle P., Kieser M., Slanger T.E., Burmeister B., Kelsen D., Niedzwiecki D., Schuhmacher C., Urba S., van de Velde C., Walsh T.N., Ychou M., Jensen K. Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adeno carcinoma: systematic review with meta analysis combining individual patient and aggregate data. Eur J Cancer. 2013 Oct; 49 (15): 3149–58. doi: 10.1016/j.ejca.2013.05.029.

13. Blank S., Stange A., Sisic L., Roth W., Grenacher L., Sterzing F., Burian M., Jäger D., Büchler M., Ott K. Preoperative therapy of esophago gastric cancer: the problem of nonresponding patients. Langenbecks Arch Surg. 2013 Feb; 398 (2): 211–20. doi: 10.1007/s00423 012 1034 5.

14. Cho H., Nakamura J., Asaumi Y., Yabusaki H., Sakon M., Takasu N., Kobayashi T., Aoki T., Shiraishi O., Kishimoto H., Nunobe S., Yanagisawa S., Suda T., Ueshima S., Matono S., Maruyama H., Tatsumi M., Seya T., Tanizawa Y., Yoshikawa T. Long term survival outcomes of advanced gastric cancer patients who achieved a pathological complete response with neoadjuvant chemotherapy: a systematic review of the literature. Ann Surg Oncol. 2015 Mar; 22 (3): 787–92. doi: 10.1245/s10434 014 4084 9

15. Kaprin A.D., Galkin V.N., Zhavoronkov L.P., Ivanov V.K., Ivanov S.A., Romanko Yu.S. The synthesis of fundamental and applied research is the basis for ensuring the level of scientific results and their introduction into medical practice. Radiation and risk. 2017; 26 (2): 26–40. doi: 10.21870 / 0131 3878 2017 26 2 26 40. [in Russian]